Quote:
Originally Posted by mcwarner1 
I would really like to see it. As I said, I've been holding a good bit of teva for a while now, but I feel like there is so much value at this low price that I should only benefit by buying more.
|
I just got in at $48.35.
And no problem. Keep in mind this is just the way I approach investing, with a Buffet, value-based, buy & hold style. First off I pulled my numbers from Google (below).
To me, Teva seems like a really diversified ADR, which spreads the risk out.
"
The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, including 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 15 generic research and development (R&D) centers operating mostly within certain manufacturing sites and 21 API manufacturing sites around the world."
Doing the math now:
Teva has a current EPS of $3.24. With a 5yr EPS avg of 34.97% and 10yr of 25.42%
So to forcast a bit lets just assume over the next 5 years they average only 15%.
1.
This gives an EPS in the 5th year of $6.52 and a total EPS over the 5 years of $25.13.
2.
There current P/E is 15.38 (the average of the stock market over the last 50 years has averaged 17). So being conservative, use a P/E of 15 and multiply by the expected EPS of the 5th year to get the expected stock price of the 5th year...(without dividends)
$6.52 x 15 = $97.8
3.
Plus add on the money earned from the dividends. They have a yield of 1.52% which works out to $0.756/share. So thier Dividend payout ratio is 23%.
So now take the total of the earnings and multiply how much you will make from dividends per share:
$25.13 x 0.23 = $5.87
4.
Add this to the stock price to get the expected 5 year price with expected dividends:
$5.87 + $97.80 = $103.67
5.
Now, Buffet only bought companies if he would earn at least 15% per year. So now we need to know what price we should buy today in order to acheive that.
$103.67 / (1.15^5) = $51.54
The current price is $49.77 meaning this company is undervalued.
In North America all of the baby boomers, now and for the next 10+ years, are going to be needing to be put on medication or more of it. It is just the way it is, look at any senior 65+, and odds are they are taking at least 1 medication for a chronic ailment. From what I have read, it is basically the same in most of Europe. There are also ever increasing generics becoming available with brand names coming off patent. This all means more demand and more revenue.
Lastly, they have high operating margain which gives them some wiggle room when times get tough, along with great revenue growth.
Just my 2 cents on TEVA. I'd love to here anyone elses views, comments, opinions, or DD on the company.
http://i210.photobucket.com/albums/b...s/TevaData.jpg